Halozyme Therapeutics, Inc. $HALO Shares Sold by TD Asset Management Inc

by · The Markets Daily

TD Asset Management Inc reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 10.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 931,704 shares of the biopharmaceutical company’s stock after selling 103,466 shares during the quarter. TD Asset Management Inc’s holdings in Halozyme Therapeutics were worth $62,704,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Marietta Investment Partners LLC lifted its position in shares of Halozyme Therapeutics by 21.1% in the fourth quarter. Marietta Investment Partners LLC now owns 35,301 shares of the biopharmaceutical company’s stock valued at $2,376,000 after acquiring an additional 6,150 shares in the last quarter. One Capital Management LLC increased its stake in Halozyme Therapeutics by 39.5% in the fourth quarter. One Capital Management LLC now owns 46,806 shares of the biopharmaceutical company’s stock valued at $3,150,000 after purchasing an additional 13,248 shares during the last quarter. Measured Wealth Private Client Group LLC increased its stake in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Impact Partnership Wealth LLC acquired a new position in Halozyme Therapeutics in the fourth quarter valued at $448,000. Finally, Norges Bank acquired a new position in Halozyme Therapeutics in the fourth quarter valued at $128,201,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Halozyme Therapeutics news, COO Cortney Caudill sold 8,857 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total transaction of $599,087.48. Following the completion of the sale, the chief operating officer directly owned 7,055 shares in the company, valued at $477,200.20. This represents a 55.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the completion of the sale, the director directly owned 43,669 shares of the company’s stock, valued at $2,891,324.49. The trade was a 3.59% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 122,107 shares of company stock worth $8,254,834 over the last three months. 2.50% of the stock is owned by insiders.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

  • Positive Sentiment: Zacks Research raised Halozyme’s earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, signaling confidence in the company’s longer-term profit growth. Halozyme Therapeutics article
  • Positive Sentiment: Analysts also increased estimates for several individual quarters in 2027, reinforcing a constructive earnings outlook for Halozyme Therapeutics. Halozyme Therapeutics article
  • Neutral Sentiment: One near-term forecast was trimmed slightly and another was revised lower, but the overall analyst tone remains mostly favorable. Halozyme Therapeutics article
  • Neutral Sentiment: Recent insider selling by the CEO was disclosed, but the trades were executed under a pre-arranged trading plan, which typically lessens investor concern. Halozyme Therapeutics article

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $71.53 on Friday. The firm has a market capitalization of $8.48 billion, a PE ratio of 25.73, a P/E/G ratio of 0.30 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The business has a 50-day moving average of $66.79 and a two-hundred day moving average of $68.74. Halozyme Therapeutics, Inc. has a 12 month low of $51.06 and a 12 month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm’s revenue was up 42.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

HALO has been the subject of several analyst reports. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. UBS Group reiterated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday. Finally, Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

View Our Latest Report on Halozyme Therapeutics

About Halozyme Therapeutics

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Featured Articles

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).